Interest of High-throughput Sequencing of RNAs for the Diagnosis of Heterogeneous Genetic Diseases

The advent of high throughput genomic DNA sequencing has led to major advances in the diagnosis of genetic diseases of heterogeneous origin. Thus, our hospital laboratory has developed in recent years several diagnostic tests based on the targeted sequencing of coding sequences of gene panels (from about twenty genes for DNA repair diseases to nearly five hundred genes for the intellectual disability). These targeted analyzes, carried out by capture, have thus solved 25 to 80% of the cases according to the indications, without allowing the diagnosis of the totality of the patients.

For these negative cases, the search for mutations in the coding sequences was then extended to Whole Exome Sequencing, thus providing several additional diagnoses.

Patients still remain without diagnosis after this exome study. These could be complex cases of genetic or even non-genetic origin, but also monogenic pathologies linked to mutations that are not identifiable by coding sequence analyzes, and especially affecting messenger RNAs.

Study Overview

• Status: Unknown
• Conditions: DNA Sequencing; Diagnosis of Genetic Diseases of Heterogeneous Origin
• Intervention / Treatment: Genetic: RNA sequencing

• Study Type: Observational
• Enrollment (Anticipated): 15

Contacts and Locations

Study Locations

• France
  • Strasbourg, France, 67091
    • Les Hôpitaux Universitaires de Strasbourg
    • Contact: Nadège CALMELS; Phone Number: +33 33 69 55 07 77; Email: nadege.calmels@chru-strasbourg.fr
    • Principal Investigator: Nadège CALMELS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient suffering from a pathology studied in the laboratory by high throughput sequencing: intellectual disability, myopathies, neurosensory disease (Bardet-Biedl syndrome, retinitis pigmentosa, ....), DNA repair diseases (Cockayne syndrome, ...)

Description

Inclusion criteria common to all participants:

• Patient minor or major
• Patient suffering from a pathology studied in the laboratory by high throughput sequencing: intellectual disability, myopathies, neurosensory disease (Bardet-Biedl syndrome, retinitis pigmentosa, ....), DNA repair diseases (Cockayne syndrome, ...)
• Sampling allowing the extraction of available RNA (or RNA available in the bank)
• Patient (or its legal representative) having already given their consent, on the one hand for carrying out genetic analyzes to determine the cause of their disease, and on the other hand for the conservation of part of their non used for further use in order to continue diagnostic investigations in the light of evolving knowledge and for research purposes.
• Patient (or its legal representative) agreeing to use data from his medical file and those associated with genetic diagnosis for research purposes
• Patient affiliated to a social security scheme Inclusion criteria for the test phase
• Pertogenous mutation (s) known Inclusion criteria for the prospective phase
• Magnetic molecular diagnosis, after the usual investigations (high-throughput sequencing of a panel of genes on genomic DNA, sequencing of exome, or even genome.

Non-inclusion criteria:

◾ Refusal of the patient (or his / her legal representative) to participate in the study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Validation phase; The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.	Genetic: RNA sequencing; Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
Prospective phase; The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.	Genetic: RNA sequencing; Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
RNA sequencing	testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing of coding regions, and its integration into hospital routine in order to improve the diagnosis of heterogeneous genetic diseases.	3 years

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): June 1, 2019
• Primary Completion (ANTICIPATED): July 1, 2019
• Study Completion (ANTICIPATED): July 1, 2022

Study Registration Dates

• First Submitted: May 31, 2019
• First Submitted That Met QC Criteria: May 31, 2019
• First Posted (ACTUAL): June 3, 2019

Study Record Updates

• Last Update Posted (ACTUAL): June 3, 2019
• Last Update Submitted That Met QC Criteria: May 31, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Genetic Diseases, Inborn
• Other Study ID Numbers: 7004 (CTEP)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No